New review charts a roadmap for biologically informed psychiatric diagnosis using biomarkers and AI.
Key Details
- 1Psychiatric diagnosis still relies on symptom checklists, lacking biological grounding.
- 2Emerging frameworks combine molecular/neuroimaging biomarkers, digital phenotyping, and machine learning integration.
- 3Large consortia (e.g., ENIGMA) tie neuroimaging findings to psychiatric conditions like schizophrenia and depression.
- 4Molecular diagnostic tests (e.g., VeriPsych, EDIT-B) have reached limited clinical adoption; most candidate biomarkers lack clinical utility so far.
- 5AI and multimodal models show promise but face challenges with limited psychiatric datasets, lack of explainability, and real-world validation.
- 6Review emphasizes that objective biological measurement should complement—not replace—clinical judgment.
Why It Matters
For radiology and imaging AI professionals, this review highlights the expanding role of neuroimaging, molecular markers, and AI in mental health, a field historically reliant on subjective measures. Robust integration of imaging and digital phenotyping could reshape diagnosis, steering research and technology development towards actionable and explainable clinical tools.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.